Border to Coast Pensions Partnership Ltd Acquires 255,348 Shares of Bio-Techne Corp $TECH

28 Jun 2026, 08:02 by Michael Walen · The Markets Daily

Border to Coast Pensions Partnership Ltd grew its holdings in shares of Bio-Techne Corp (NASDAQ:TECH – Free Report) by 100.1% during the 1st quarter, HoldingsChannel reports. The fund owned 510,333 shares of the biotechnology company’s stock after acquiring an additional 255,348 shares during the quarter. Border to Coast Pensions Partnership Ltd’s holdings in Bio-Techne were worth $26,752,000 at the end of the most recent reporting period.

A number of other hedge funds have also recently made changes to their positions in TECH. Danske Bank A S purchased a new stake in shares of Bio-Techne in the 4th quarter valued at $29,000. eCIO Inc. bought a new position in shares of Bio-Techne during the 4th quarter valued at $30,000. Measured Wealth Private Client Group LLC purchased a new position in Bio-Techne in the 3rd quarter worth $32,000. iSAM Funds UK Ltd purchased a new position in Bio-Techne in the 3rd quarter worth $33,000. Finally, EverSource Wealth Advisors LLC lifted its stake in Bio-Techne by 506.3% in the second quarter. EverSource Wealth Advisors LLC now owns 673 shares of the biotechnology company’s stock worth $35,000 after purchasing an additional 562 shares during the last quarter. 98.95% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

TECH has been the subject of several analyst reports. Zacks Research lowered shares of Bio-Techne from a “hold” rating to a “strong sell” rating in a research report on Monday, June 8th. Citigroup downgraded Bio-Techne from a “buy” rating to a “neutral” rating in a report on Friday. Stephens set a $73.00 target price on Bio-Techne and gave the company an “equal weight” rating in a research note on Friday. Weiss Ratings raised Bio-Techne from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Thursday, May 7th. Finally, Stifel Nicolaus set a $50.00 target price on Bio-Techne in a report on Thursday, May 7th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $68.07.

View Our Latest Research Report on Bio-Techne

Bio-Techne Trading Up 0.4%

NASDAQ:TECH opened at $71.00 on Friday. The firm has a market capitalization of $11.12 billion, a P/E ratio of 102.90, a P/E/G ratio of 6.88 and a beta of 1.37. The company has a quick ratio of 3.18, a current ratio of 4.49 and a debt-to-equity ratio of 0.10. The company has a fifty day moving average of $52.95 and a 200 day moving average of $57.09. Bio-Techne Corp has a 52 week low of $43.19 and a 52 week high of $72.16.

Bio-Techne (NASDAQ:TECH – Get Free Report) last announced its quarterly earnings results on Wednesday, May 6th. The biotechnology company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.55 by ($0.02). Bio-Techne had a return on equity of 13.57% and a net margin of 9.05%.The firm had revenue of $311.42 million during the quarter, compared to the consensus estimate of $316.11 million. During the same period last year, the business earned $0.56 EPS. Bio-Techne’s revenue was down 1.5% on a year-over-year basis. On average, research analysts predict that Bio-Techne Corp will post 1.65 earnings per share for the current year.

Bio-Techne Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, May 29th. Stockholders of record on Monday, May 18th were issued a dividend of $0.08 per share. This represents a $0.32 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Monday, May 18th. Bio-Techne’s dividend payout ratio is currently 46.38%.

Key Stories Impacting Bio-Techne

Here are the key news stories impacting Bio-Techne this week:

Positive Sentiment: Merck KGaA’s all-cash buyout offer gives Bio-Techne shareholders a clear takeover price and a premium valuation anchor. Merck KGaA, Darmstadt, Germany, Agrees to Acquire Bio-Techne, Strengthening Leadership Position in Fast-Growing Life Sciences Markets
Positive Sentiment: Analyst actions were mixed but included an upgrade from Evercore to strong-buy and a price-target increase from Baird to $73, reinforcing the view that the shares were moving toward deal value.
Neutral Sentiment: Unusual call-option activity suggests traders are positioning for further merger-related volatility, but that activity does not change the takeover terms.
Negative Sentiment: Shareholder-law-firm investigations have begun over whether the Merck deal provides a fair price, which could add some headline risk and scrutiny around the transaction. SHAREHOLDER ALERT: The M&A Class Action Firm Announces An Investigation of Bio-Techne Corporation (NASDAQ: TECH)

About Bio-Techne

(Free Report)

Bio-Techne Corporation (NASDAQ:TECH) is a global life sciences company that develops, manufactures and sells high-quality reagents, instruments and services for the research, diagnostic and bioprocessing markets. Its core product offerings include recombinant proteins, antibodies, immunoassays, nucleic acid probes and kits, single-cell analysis solutions and automated protein analysis systems. Flagship brands such as R&D Systems, Novus Biologicals, ProteinSimple and Advanced Cell Diagnostics provide researchers and clinicians with reliable tools for cell biology, immunology, proteomics and genomics applications.

Headquartered in Minneapolis, Minnesota, Bio-Techne serves customers across North America, Europe and the Asia-Pacific region through a combination of direct sales, distributors and strategic partnerships.